Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 59Gastrointestinal Stromal Tumors 22Neoplasms 18Breast Neoplasms 16Kidney Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Carcinoma 7Colorectal Neoplasms 6Neoplasm Metastasis 5Stomach Neoplasms 4Neuroendocrine Tumors 4Kidney Diseases 4Gastrointestinal Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Hepatocellular 4Adenoma, Islet Cell 4Prostatic Neoplasms 3Urologic Neoplasms 2Urogenital Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Financial Stress 2Urothelial Cancer 1Urologic Diseases 1Thyroid Neoplasms 1Somatostatinoma 1Solid Tumors 1Solid Tumor 1Primary hyperoxaluria type 2 1Patient Preference 1

Interventions

Gemcitabine 4Cisplatin 4Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1avelumab 1atezolizumab 1Tiragolumab 1Sunitinib 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urothelial Cancer × Sunitinib × Clear all
NCT00821327 2016-10-25

Gemzar, Cisp, Sunitinib Urothelial Ca

US Oncology Research

Phase 2 Completed
36 enrolled 9 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡